Posted by Michael Wonder on 22 Feb 2016
FDA accepts Sanofi new drug application for once-daily fixed-dose combination of insulin glargine and lixisenatide
22 February 2016 - Following the redemption of a Priority Review Voucher with the submission, an FDA decision is anticipated in August 2016.
For more details, go to: http://en.sanofi.com/NasdaQ_OMX/local/press_releases/fda_accepts_sanofi_new_drug_ap_1987801_22-02-2016!07_00_00.aspx
